Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections

Sims Matthew; Mariyanovski Valeri; McLeroth Patrick; Akers Wayne; Lee Yu-Chieh; Brown Michelle L.; Du Jiejun; Pedley Alison; Kartsonis Nicholas A.; Paschke Amanda

首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections

【24h】

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections

机译：预期，随机，双盲，相2剂量测量研究比较伊翅尼/氯斯坦加蛋白质/含有IMIPENEM / Cilastatin的疗效和安全性在复杂的泌尿道感染患者中的疗效和安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives: The b-lactamase inhibitor relebactam can restore imipenem activity against imipenem nonsusceptible pathogens.

机译：目的：B-乳酰胺酶抑制剂重新发行可以恢复针对亚杉NONSCONCOPIBLE病原体的IMIPENEM活性。

著录项

来源
《The Journal of Antimicrobial Chemotherapy》 |2017年第9期|共11页
作者
Sims Matthew; Mariyanovski Valeri; McLeroth Patrick; Akers Wayne; Lee Yu-Chieh; Brown Michelle L.; Du Jiejun; Pedley Alison; Kartsonis Nicholas A.; Paschke Amanda;
展开▼
作者单位

William Beaumont Hosp 3555 W Thirteen Mile Rd Royal Oak MI 48073 USA;

Univ Hosp NI Pirogov Blvd Totleben 21 Sofia Bulgaria;

Covance Inc Carnegie Ctr 210 Princeton NJ 08540 USA;

Covance Inc Carnegie Ctr 210 Princeton NJ 08540 USA;

Covance Inc Carnegie Ctr 210 Princeton NJ 08540 USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献

1. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections [J] . Sims Matthew, Mariyanovski Valeri, McLeroth Patrick, The Journal of Antimicrobial Chemotherapy . 2017,第9期

机译：预期，随机，双盲，相2剂量测量研究比较伊翅尼/氯斯坦加蛋白质/含有IMIPENEM / Cilastatin的疗效和安全性在复杂的泌尿道感染患者中的疗效和安全性
2. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial [J] . Portsmouth Simon, van Veenhuyzen David, Echols Roger, The Lancet infectious diseases . 2018,第12期

机译：Cefideroon与Imipenem-Cilastatis治疗革兰阴性尿膜异常引起的复杂尿路感染：2阶段，随机，双盲，非劣等试验
3. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection [J] . Lucasti Christopher, Vasile Liviu, Sandesc Dorel, Antimicrobial agents and chemotherapy. . 2016,第10期

机译：雷贝巴坦与亚胺培南-西拉他汀在复杂腹腔内感染患者中的2期剂量范围研究
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Phase 2 Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection [O] . Christopher Lucasti, Liviu Vasile, Dorel Sandesc, 2016

机译：雷贝巴坦与亚胺培南-西拉他汀在复杂腹腔内感染患者中的2期剂量范围研究
6. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections [O] . Matthew Sims, Valeri Mariyanovski, Patrick McLeroth, 2017

机译：预期，随机，双盲，相2剂量测量研究比较亚氨em / cilastatin Plus重新分泌蛋白/西兰拉汀的疗效和安全性在复杂的泌尿道感染患者中的疗效和安全性

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections

摘要

著录项

相似文献

相关主题

期刊订阅